Phase III additional clinical study of 111in-pentetreotide (MP-1727): Diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptors

Tsuneo Saga, Nagara Tamaki, Keiichi Itoi, Tetsuro Yamazaki, Keigo Endo, Goro Watanabe, Hirotaka Maruno, Rikuo Machinami, Kiyoshi Koizumi, Taro Ichikawa, Hiroshi Takami, Miyuki Ishibashi, Atsushi Kubo, Kiyoko Kusakabe, Yukio Hirata, Yuji Murata, Yukitaka Miyachi, Masahiko Tsubuku, Harumi Sakahara, Kazuhiro KatadaNorihisa Tonami, Kazutaka Yamamoto, Junji Konishi, Masayuki Imamura, Ryuichiro Doi, Akira Shimatsu, Shinzaburo Noguchi, Yoshinao Hasegawa, Osamu Ishikawa, Yuji Watanabe, Masayuki Nakajo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Additional phase III multicenter clinical study was performed to investigate the efficacy, safety, and usefulness of somatostatin receptor scintigraphy using 111In-pentetreotide (MP-1727), which binds to somatostatin receptors. Forty patients were included in the study; Group A: 18 patients, gastrointestinal hormone producing tumors had been detected with conventional imaging modalities, Group B: 22 patients, no tumors had been detected with conventional imaging modalities in spite of high serum hormone levels. By comparing the results of the octreotide suppression test, 12/16 cases (75.0%) of Group A and 11/19 cases (57.9%) of Group B were assessed as "effective." By comparing the results of immunohistological examination. 5/9 cases (55.6%) of Group A and 2/4 cases (50.0%) of Group B were assessed as "effective." Severe adverse events were not observed in any of the evaluable 35 cases. MP-1727 was judged as clinically useful in 11/16 cases (68.8%) of Group A and 5/19 cases (26.3%) of group B. These results suggest that MP-1727 scintigraphy is very useful for the diagnosis and decision of the therapeutic strategy of gastrointestinal hormone producing tumors.

Original languageEnglish
Pages (from-to)185-203
Number of pages19
JournalKakuigaku
Volume40
Issue number2
Publication statusPublished - 2003 Jan 1
Externally publishedYes

Keywords

  • Gastroenteropancreatic tumor
  • In-pentetreotide
  • Octreotide suppression test
  • Scintigraphy
  • Somatostatin receptor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Phase III additional clinical study of <sup>111</sup>in-pentetreotide (MP-1727): Diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptors'. Together they form a unique fingerprint.

  • Cite this

    Saga, T., Tamaki, N., Itoi, K., Yamazaki, T., Endo, K., Watanabe, G., Maruno, H., Machinami, R., Koizumi, K., Ichikawa, T., Takami, H., Ishibashi, M., Kubo, A., Kusakabe, K., Hirata, Y., Murata, Y., Miyachi, Y., Tsubuku, M., Sakahara, H., ... Nakajo, M. (2003). Phase III additional clinical study of 111in-pentetreotide (MP-1727): Diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptors. Kakuigaku, 40(2), 185-203.